A resolution expressing support for the designation of the month of May 2026 as "Progressive Supranuclear Palsy and Corticobasal Degeneration Awareness Month".

Purpose and scope

• Bill: S. Res. 752 (Senate, 119th Congress, 2nd Session)
• Type: A Senate resolution expressing support for designating May 2026 as “Progressive Supranuclear Palsy and Corticobasal Degeneration Awareness Month.”

• Sponsor: Senator Richard Blumenthal (co-sponsor)

• Core goal: Show formal Senate support for recognizing May 2026 as an awareness month dedicated to Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration (CBD), and to promote awareness, research, and support related to these diseases.

Main purpose and intent

• Raise awareness about PSP and CBD, two rare, adult-onset, rapidly progressing neurodegenerative disorders with distinct trajectories and care needs.
• Highlight the challenges of diagnosis, care, and access to neurology specialists.
• Emphasize the need for ongoing research, education, and support services to improve quality of life, advance diagnosis, prevention, treatments, and potential cures.
• Recognize and commend the efforts of patients, families, caregivers, healthcare professionals, researchers, and advocacy organizations.

Key provisions and provisions impact

As a resolution, the text does not enact new law or create programs; rather, it:

• Declares Senate support for designating May 2026 as PSP and CBD Awareness Month.
• Endorses the goals and ideals of PSP/CBD Awareness Month.
• Supports continued research on diagnosis, prevention, treatments, and cures for PSP and CBD.
• Recognizes the resilience of affected communities.
• Commends individuals and groups working to improve the lives of people with PSP and CBD.

Who/what would be affected

• Individuals diagnosed with PSP or CBD, their families and caregivers.
• Healthcare professionals, particularly neurology specialists and care teams.
• Research communities and organizations focused on PSP and CBD.
• Communities nationwide that may participate in awareness activities during May 2026.

Procedural and timeline aspects

• Action: Refer to the Senate Committee on Health, Education, Labor, and Pensions for consideration.
• Date of introduction: May 21, 2026.
• Since this is a resolution, it expresses opinion and intent rather than creating binding law or new programs.
• If adopted, the designation would apply specifically to May 2026 as an awareness month, with potential dissemination through allied health and advocacy channels.

Noticeable details

• Estimated disease prevalence cited in the text: approximately 30,000 Americans with PSP and about 2,000 Americans with CBD.
• Emphasizes lack of disease-modifying treatments and the need for better understanding of environmental and genetic factors.
• Highlights common diagnostic delays and the importance of access to neurology professionals specialized in these diseases.

This summary provides the bill’s aim, the substantive statements it makes about PSP and CBD, who would be affected, and the procedural status and timeline for designation.